AMENDMENT NO. 1 TO THE TECHNOLOGY TRANSFER, VALIDATION AND COMMERCIAL FILL/FINISH SERVICES AGREEMENTTechnology Transfer, Validation and Commercial Fill/Finish Services Agreement • February 25th, 2021 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 (this “Amendment”) is made and entered into as of December 18th, 2020 (the “Amendment Effective Date”), by and between Revance Therapeutics, Inc., (“Client”), and Ajinomoto Althea, Inc., dba Aji Bio-Pharma Services (“ABPS”).
AMENDMENT NO. 2 TO THE TECHNOLOGY TRANSFER, VALIDATION AND COMMERCIAL FILL/FINISH SERVICES AGREEMENTTechnology Transfer, Validation and Commercial Fill/Finish Services Agreement • February 28th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 (this “Amendment”) is made and entered into as of February 23, 2024 (the “Amendment Effective Date”), by and between Revance Therapeutics, Inc., (“Client”), and Ajinomoto Althea, Inc., dba Ajinomoto Bio-Pharma Services, a California (formerly Delaware) corporation (“ABPS”).
Technology Transfer, Validation and Commercial Fill/Finish Services AgreementTechnology Transfer, Validation and Commercial Fill/Finish Services Agreement • February 28th, 2022 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Agreement”) is entered into as of the 14th day of March, 2017 (“Effective Date”) by and between Revance Therapeutics, Inc., a Delaware corporation, having its principal place of business at 7555 Gateway Blvd., Newark, CA 94560 (“Client”), and Ajinomoto Althea, Inc., a Delaware corporation, with a place of business located at 11040 Roselle Street, San Diego, CA 92121 (“Althea”);
Commercial Fill/Finish Services AgreementTechnology Transfer, Validation and Commercial Fill/Finish Services Agreement • May 9th, 2017 • Revance Therapeutics, Inc. • Pharmaceutical preparations • California
This Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Agreement”) is entered into as of the 14th day of March, 2017 (“Effective Date”) by and between Revance Therapeutics, Inc., a Delaware corporation, having its principal place of business at 7555 Gateway Blvd., Newark, CA 94560 (“Client”), and Ajinomoto Althea, Inc., a Delaware corporation, with a place of business located at 11040 Roselle Street, San Diego, CA 92121 (“Althea”);
